TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23359970
Drug: Fuzheng Fujia
Normalized name: BENZALKONIUM CHLORIDE 0.2 g in 100 mL / DIDECYLDIMONIUM CHLORIDE 0.6 g in 100 mL TOPICAL SPRAY [FVJIA disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Fujia Mixture (FFM), 3 times daily for one month as 1 therapeutic course, in addition to Levothyroxine Sodium Tablet (LST) as routine treatment.
Study: 23359970
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine Sodium Tablet (LST) as routine treatment.
Study: 19852964
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a plus ribavirin (HCV RNA >500,000 IU/mL)
Study: 19852964
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b plus ribavirin (HCV RNA >500,000 IU/mL)
Study: 19852964
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Study: 19852964
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Study: 18066962
Drug: Thrombophilia screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombophilia screening protocol including hereditary thrombophilic disorders, antiphospholipid antibodies, and hyperhomocysteinemia.
Study: 1931532
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (therapeutic dosage, serum levels of 10-20 micrograms/ml) for two months
Study: 7145250
Drug: Clonidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.4 mg
Study: 21126295
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (all-in-one self-etch adhesive; 3M ESPE) after water cleansing
Study: 12117084
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 4% nasal solution
Study: 2793699
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose plus electrolytes (D5W) infusion for 48 hours
Study: 669542
Drug: Benzopyrone preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyrone preparation (Venalot)
Study: 669542
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (analgesic only)
Study: 27831502
Drug: Pertuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab and trastuzumab with chemotherapy (paclitaxel, epirubicin, cyclophosphamide)
Study: 17400953
Drug: Commit (medicinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commit (medicinal nicotine lozenge)
Study: 8385284
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20 mg
Study: 7589046
Drug: Combined atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined atenolol 100 mg and nifedipine retard 20 mg
Study: 7589046
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (active control)
Study: 7468987
Drug: Pentazocine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (higher dose)
Study: 7468987
Drug: Pentazocine (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (lower dose)
Study: 31274119
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (4 doses of Norfloxacin 400mg, twice a day for two days)
Study: 27898215
Drug: Aggressive drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive drainage (daily drainage)
Study: 23218591
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (15 min prior to radiation)
Study: 22072355
Drug: Pre-surgical dietetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-surgical dietetic guidance and intravenous fluids for malnourished patients (DNS)
Study: 19698938
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) with medication
Study: 19698938
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) without medication
Study: 11352879
Drug: Prolonged antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antiplatelet therapy (6 months of clopidogrel and aspirin)
Study: 11352879
Drug: Active gamma‐radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gamma‐radiation treatment (1 month of antiplatelet therapy)
Study: 11352879
Drug: Placebo historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo historical control group (1 month of antiplatelet therapy)
Study: 3622314
Drug: Controlled-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release isosorbide 5-mononitrate 60 mg once daily
Study: 3622314
Drug: Controlled-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release isosorbide 60 mg once daily
Study: 3622314
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of isosorbide 20 mg 3 times daily
Study: 1982280
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg epinastine
Study: 1982280
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg epinastine
Study: 1982280
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg epinastine
Study: 26561784
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g bioactive collagen peptides (BCP) daily for 6 months
Study: 19808198
Drug: MAGE‐A3 antigen‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE‐A3 antigen‐specific cancer immunotherapeutic (ASCI) agents
Study: 17582289
Drug: MPO level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPO level > or = 62.9 AUU/L
Study: 17582289
Drug: MPO level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPO level when TnI <= 0.05 ng/ml
Study: 15364316
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo with open-label antihypertensive therapy)
Study: 12389143
Drug: Gabapentin 2000
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 2000 mg/day
Study: 9661119
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg recombinant human growth hormone (rhGH)
Study: 9661119
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg recombinant human growth hormone (rhGH)
Study: 23425012
Drug: Dapagliflozin 2.5
Normalized name: dapagliflozin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 2.5 to 5 mg
Study: 17377401
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) - 2 puffs administered at 0, 20, 40 min
Study: 17377401
Drug: Terbutaline (T)
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (T) - 2 puffs administered at 0, 20, 40 min
Study: 15188805
Drug: Phenobarbital 20
Normalized name: phenobarbital 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 20 mg/kg i.v. within first six hours of life
Study: 11683930
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus AMPC 750 mg and CAM 200 mg b.i.d. (Group B-LAC200)
Study: 11683930
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg, AMPC 750 mg and CAM 400 mg b.i.d. (Group C-LAC400)
Study: 11683930
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg twice a day (Group A-LPZ-only)
Study: 2917701
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice daily) + Lovastatin (20 mg twice daily)
Study: 30142037
Drug: Strips (White
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strips (White Strips, Oral-B)
Study: 19486269
Drug: oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral and denture hygiene instructions
Study: 19486269
Drug: instructions associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: instructions associated with the home use of a disclosing agent (1% neutral red)
Study: 15682849
Drug: Tc‐99m ethylenedicysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m ethylenedicysteine (3.7 MBq/kg body weight) and furosemide at an appropriate dose administered intravenously
Study: 11568738
Drug: High-dose UVA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UVA1 phototherapy (<=130 J/cm2)
Study: 11568738
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1 phototherapy (half the dose of high-dose)
Study: 2594037
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (3000 cGy of electron-beam radiation + parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine)
Study: 2594037
Drug: Sequential topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential topical treatment
Study: 2594037
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy and Sequential topical treatment
Study: 4804456
Drug: Diabetics not
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetics not on any form of treatment
Study: 31409915
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg in addition to baseline dose of statin
Study: 29020936
Drug: Staggered sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staggered sugammadex (1 mg/kg before extubation and 1 mg/kg after extubation)
Study: 29020936
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus sugammadex (2 mg/kg)
Study: 29020936
Drug: Neostigmine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.02 mg/kg with glycopyrrolate)
Study: 23455877
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (both with and without counseling)
Study: 18237355
Drug: Alternative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatments (MVP, vinorelbine, active symptom control)
Study: 10987238
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus manual lymphatic drainage (MLD) 8 times in 2 weeks and training in self-massage
Study: 10987238
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (compression garment, exercises, information about lymphedema and skin care)
Study: 8291869
Drug: Polyestradiol phosphate
Normalized name: POLYESTRADIOL PHOSPHATE
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyestradiol phosphate (PEP) 160 mg/month
Study: 3034016
Drug: Ramipril (HOE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (HOE 498) 5 or 10 mg
Study: 24507830
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone (1,000 μg/d)
Study: 24507830
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone (250 μg/d)
Study: 23129488
Drug: Melatonin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.5 mg to 12 mg depending on response)
Study: 10877005
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg)
Study: 18621928
Drug: Rivaroxaban 30
Normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 30 mg once daily
Study: 18621928
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (low-molecular-weight heparin followed by vitamin K antagonists)
Study: 16100132
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management (DM) program with care coordination, family support, teaching, and monitoring of therapies from a team of advanced-practice nurses, a geriatrician, and a pulmonologist for 2 months post-hospital discharge.
Study: 10354963
Drug: lamivudine/zidovudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine/zidovudine combination tablet after an overnight fast
Study: 10354963
Drug: lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 150 mg tablet and zidovudine 300 mg tablet administered concurrently after an overnight fast
Study: 10354963
Drug: lamivudine/zidovudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine/zidovudine combination tablet 5 minutes after a standardized high-fat breakfast
Study: 7796357
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg four times daily
Study: 678769
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of depot penicillin at the time of suture
Study: 27480573
Drug: Equicrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equicrestal implants (G1, n=28)
Study: 27480573
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants (G2, n=27)
Study: 26156901
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean 500 mg/day)
Study: 26156901
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean 5.2 mg/day)
Study: 19469706
Drug: sorivudine cream
Normalized name: Brivudine
DrugBank: Sorivudine (DB11998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorivudine cream
Study: 16753975
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency chest wall oscillation (HFCWO) administered twice-daily for 15 min duration plus standard care
Study: 9286741
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,000 mg/day for 8 days)
Study: 8356859
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 20 ml of 0.125% bupivacaine and 2 mg of morphine administered epidurally about 30 min before the end of the operation
Study: 9279969
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg day-1
Study: 2887190
Drug: Labetalol 200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200-800 mg day-1
Study: 2887190
Drug: Pindolol 10-30
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 10-30 mg day-1
Study: 2887190
Drug: Captopril 25-100
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25-100 mg day-1
Study: 6130944
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four drugs
Study: 30382819
Drug: Open lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open lung approach (OLA) with PEEP titration, external PEEP selected was 6 ± 0.8 cmH2O.
Study: 30382819
Drug: Open lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open lung approach (OLA) with PEEP titration.
Study: 27965838
Drug: Immediate tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate tumor resection after stopping chemotherapy
Study: 27965838
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of chemotherapy before surgery
Study: 18975535
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ketamine (300-400 microg x kg(‐1) x hr(‐))
Study: 16875724
Drug: Exercise Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Prescription Model (EPM) - 30-minute continuous activity, 3-4 days per week
Study: 12954465
Drug: Instrumental Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Activities of Daily Living
Study: 10812039
Drug: 0.5 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mol/L sodium lactate infused over 20 min
Study: 9017056
Drug: Amvisc with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amvisc with aspiration and topical timolol
Study: 1517815
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (CDDP)
Study: 24531687
Drug: PG201 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG201 600 mg
Study: 22259009
Drug: Regadenoson 0.4
Normalized name: REGADENOSON 0.4MG/5ML INJ VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson 0.4 mg intravenous injection
Study: 19473285
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg taken once daily
Study: 15365570
Drug: Irinotecan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan monotherapy (350 mg m(‐2) once every 3 weeks)
Study: 11239541
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg; n = 50)
Study: 11239541
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined 17-beta-estradiol (2 mg) and norethindrone acetate (1 mg; n = 50)
Study: 9737353
Drug: prednisolone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone, 10 mg twice daily
Study: 7508194
Drug: Human galanin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human galanin (500 micrograms) in saline (100 ml)
Study: 7508194
Drug: Saline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (100 ml)
Study: 2727326
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of breathing patterns
Study: 26220762
Drug: Alfaxalone-dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone-dexmedetomidine (0.3 mg 100 mL(‐1))
Study: 19854114
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of estrogen receptor (ER) negative tumor
Study: 14722364
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (20 mg elemental iron)
Study: 14722364
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education with supplementation (20 mg elemental iron)
Study: 10745678
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL black currant/apple juice (1:1)
Study: 10745678
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL black currant/apple juice (1:1)
Study: 10745678
Drug: 1500 mL
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mL black currant/apple juice (1:1)
Study: 10745678
Drug: Juice intervention
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice intervention (all doses)
Study: 3881960
Drug: Combined estrogen-androgen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen-androgen drug
Study: 29790266
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin 300 mg twice daily for 5 days
Study: 26600073
Drug: Seven days
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days a week individual therapy
Study: 26600073
Drug: Five days
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five days a week circuit class therapy
Study: 22305998
Drug: aliskiren/amlodipine/HCTZ 300/10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: aliskiren/amlodipine/HCTZ 300/10/25 mg
Study: 22305998
Drug: aliskiren/amlodipine 300/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: aliskiren/amlodipine 300/10 mg
Study: 18363895
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clevudine once daily for 12 weeks
Study: 18363895
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg clevudine once daily for 12 weeks
Study: 18363895
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clevudine once daily for 12 weeks
Study: 16240065
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation using an oral sodium phosphate solution and rectal enema on the morning of the procedure.
Study: 16240065
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation (control group).